Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
Cytokines have long been recognized for their potential in cancer immunotherapy, but achieving clinical success has remained a challenge.
The recently published research article, “SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy,” represents a significant step forward in cytokine-based therapies.
We’re thrilled to share that LBG’s DJ Rezac contributed to this groundbreaking work, alongside an incredible team of researchers: John Cini, Richard T. Kenney, Susan Dexter, Stephen J. McAndrew, Rukiye-Nazan Eraslan, Rich Brody, Rebecca Boohaker, Susan E. Lapi, and Pankaj Mohan.
This innovative platform offers new hope for advancing cancer treatments by enhancing IL-12 delivery to the tumor microenvironment, improving therapeutic efficacy, and addressing toxicity challenges seen in prior approaches.
Read the full article to learn more about this project and technological approach.